This report was first published by Endpoints News. To see the original version, click here
Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place.
The Japanese drugmaker will buy about $2.13 billion worth of new shares in ViiV Healthcare, doubling its stake in the company to just over 20%, according to a Tuesday release. ViiV will cancel Pfizer’s holding, paying the pharma giant almost $1.88 billion in the process.
您已阅读39%（498字），剩余61%（782字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。